| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 59 | 2023 | 232 | 15.410 |
Why?
|
| Heart Failure | 83 | 2023 | 1180 | 14.830 |
Why?
|
| Ventricular Dysfunction, Right | 35 | 2023 | 117 | 10.010 |
Why?
|
| Heart-Assist Devices | 40 | 2023 | 221 | 9.450 |
Why?
|
| Pulmonary Artery | 27 | 2021 | 323 | 7.010 |
Why?
|
| Ventricular Function, Right | 26 | 2022 | 103 | 6.300 |
Why?
|
| Pulmonary Wedge Pressure | 23 | 2022 | 102 | 6.240 |
Why?
|
| Vascular Resistance | 25 | 2021 | 179 | 5.890 |
Why?
|
| Heart Transplantation | 27 | 2022 | 328 | 5.010 |
Why?
|
| Hemodynamics | 26 | 2022 | 705 | 4.630 |
Why?
|
| Cardiac Catheterization | 24 | 2022 | 419 | 4.500 |
Why?
|
| Heart Ventricles | 29 | 2021 | 738 | 4.100 |
Why?
|
| Stroke Volume | 29 | 2022 | 586 | 3.420 |
Why?
|
| Exercise Tolerance | 8 | 2021 | 75 | 2.400 |
Why?
|
| Humans | 167 | 2023 | 68618 | 2.010 |
Why?
|
| Arterial Pressure | 7 | 2020 | 47 | 1.940 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2019 | 277 | 1.930 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 9 | 2020 | 75 | 1.770 |
Why?
|
| Ventricular Function, Left | 10 | 2021 | 481 | 1.740 |
Why?
|
| Retrospective Studies | 60 | 2022 | 7277 | 1.720 |
Why?
|
| Vasodilator Agents | 8 | 2023 | 138 | 1.550 |
Why?
|
| Middle Aged | 83 | 2022 | 21147 | 1.500 |
Why?
|
| Registries | 10 | 2021 | 733 | 1.460 |
Why?
|
| Female | 96 | 2022 | 38074 | 1.390 |
Why?
|
| Heart Rate | 5 | 2020 | 568 | 1.390 |
Why?
|
| Prognosis | 26 | 2021 | 2093 | 1.330 |
Why?
|
| Male | 91 | 2022 | 37321 | 1.300 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 161 | 1.260 |
Why?
|
| Aged | 54 | 2022 | 14862 | 1.200 |
Why?
|
| Heart Conduction System | 3 | 2017 | 119 | 1.150 |
Why?
|
| Pulmonary Circulation | 5 | 2021 | 79 | 1.130 |
Why?
|
| Echocardiography | 14 | 2022 | 515 | 1.110 |
Why?
|
| Scleroderma, Systemic | 8 | 2021 | 446 | 1.100 |
Why?
|
| Familial Primary Pulmonary Hypertension | 7 | 2021 | 25 | 1.090 |
Why?
|
| Heart Atria | 3 | 2022 | 206 | 1.080 |
Why?
|
| Blood Pressure | 7 | 2021 | 1451 | 1.040 |
Why?
|
| Follow-Up Studies | 28 | 2021 | 3259 | 0.990 |
Why?
|
| Adult | 46 | 2022 | 21403 | 0.930 |
Why?
|
| Cardiac Output | 5 | 2022 | 133 | 0.890 |
Why?
|
| Myocardial Contraction | 5 | 2021 | 383 | 0.860 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2021 | 174 | 0.860 |
Why?
|
| Pacemaker, Artificial | 2 | 2021 | 157 | 0.810 |
Why?
|
| Treatment Outcome | 27 | 2022 | 7029 | 0.780 |
Why?
|
| Survival Rate | 12 | 2021 | 1056 | 0.770 |
Why?
|
| Ventricular Pressure | 6 | 2022 | 82 | 0.750 |
Why?
|
| Prospective Studies | 18 | 2022 | 3705 | 0.740 |
Why?
|
| Postoperative Complications | 7 | 2019 | 1615 | 0.740 |
Why?
|
| Risk Factors | 21 | 2022 | 5731 | 0.730 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2021 | 85 | 0.720 |
Why?
|
| Cardiotonic Agents | 3 | 2023 | 71 | 0.710 |
Why?
|
| Sildenafil Citrate | 1 | 2020 | 23 | 0.710 |
Why?
|
| Diastole | 3 | 2021 | 161 | 0.710 |
Why?
|
| Electrocardiography | 9 | 2021 | 601 | 0.690 |
Why?
|
| Waiting Lists | 7 | 2021 | 104 | 0.690 |
Why?
|
| Antihypertensive Agents | 3 | 2020 | 498 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 101 | 0.670 |
Why?
|
| Heart Arrest | 1 | 2020 | 113 | 0.660 |
Why?
|
| Liver Transplantation | 1 | 2022 | 400 | 0.640 |
Why?
|
| Predictive Value of Tests | 13 | 2021 | 1465 | 0.630 |
Why?
|
| Patient Selection | 3 | 2021 | 592 | 0.630 |
Why?
|
| Cardiomyopathies | 5 | 2022 | 167 | 0.630 |
Why?
|
| Endothelin-1 | 1 | 2019 | 122 | 0.620 |
Why?
|
| Singing | 1 | 2018 | 5 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 772 | 0.610 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 219 | 0.610 |
Why?
|
| Exercise | 5 | 2021 | 658 | 0.610 |
Why?
|
| United States | 21 | 2022 | 7367 | 0.580 |
Why?
|
| Focus Groups | 1 | 2018 | 247 | 0.580 |
Why?
|
| Cardiac Resynchronization Therapy | 5 | 2021 | 119 | 0.570 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 536 | 0.560 |
Why?
|
| Shock, Cardiogenic | 3 | 2021 | 23 | 0.550 |
Why?
|
| Ventricular Function | 1 | 2016 | 93 | 0.550 |
Why?
|
| Heart Diseases | 2 | 2017 | 276 | 0.550 |
Why?
|
| Risk Assessment | 11 | 2022 | 2007 | 0.520 |
Why?
|
| Heart | 3 | 2022 | 850 | 0.520 |
Why?
|
| Vimentin | 1 | 2015 | 47 | 0.510 |
Why?
|
| Pyridazines | 3 | 2023 | 7 | 0.510 |
Why?
|
| Dobutamine | 1 | 2015 | 25 | 0.500 |
Why?
|
| Endarterectomy | 1 | 2015 | 22 | 0.500 |
Why?
|
| Digoxin | 1 | 2014 | 24 | 0.490 |
Why?
|
| Preoperative Period | 2 | 2017 | 50 | 0.490 |
Why?
|
| Ventricular Dysfunction | 1 | 2014 | 15 | 0.490 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 249 | 0.490 |
Why?
|
| Tachycardia | 1 | 2014 | 53 | 0.490 |
Why?
|
| Tissue and Organ Procurement | 3 | 2022 | 164 | 0.490 |
Why?
|
| Graft Survival | 3 | 2018 | 465 | 0.480 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 168 | 0.470 |
Why?
|
| Kidney Transplantation | 1 | 2022 | 839 | 0.470 |
Why?
|
| Cohort Studies | 15 | 2022 | 2358 | 0.470 |
Why?
|
| Exercise Test | 6 | 2021 | 242 | 0.440 |
Why?
|
| Glomerular Filtration Rate | 4 | 2021 | 274 | 0.440 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2021 | 83 | 0.430 |
Why?
|
| Autoantibodies | 1 | 2015 | 434 | 0.420 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 253 | 0.420 |
Why?
|
| Thermodilution | 3 | 2022 | 20 | 0.410 |
Why?
|
| Oxygen Consumption | 3 | 2022 | 258 | 0.400 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 3 | 2020 | 25 | 0.400 |
Why?
|
| Hospitalization | 5 | 2022 | 978 | 0.400 |
Why?
|
| Graft Rejection | 1 | 2015 | 458 | 0.400 |
Why?
|
| Thromboembolism | 2 | 2022 | 91 | 0.390 |
Why?
|
| Reproducibility of Results | 7 | 2020 | 2077 | 0.370 |
Why?
|
| Aged, 80 and over | 11 | 2022 | 4848 | 0.360 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 940 | 0.360 |
Why?
|
| Incidence | 10 | 2021 | 1603 | 0.330 |
Why?
|
| Systole | 3 | 2021 | 149 | 0.330 |
Why?
|
| Valsalva Maneuver | 2 | 2019 | 10 | 0.330 |
Why?
|
| Photoplethysmography | 2 | 2019 | 15 | 0.320 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 28 | 0.320 |
Why?
|
| Histamine H2 Antagonists | 3 | 2018 | 45 | 0.320 |
Why?
|
| Prosthesis Implantation | 3 | 2018 | 83 | 0.310 |
Why?
|
| Compliance | 3 | 2020 | 26 | 0.310 |
Why?
|
| Epoprostenol | 2 | 2018 | 71 | 0.300 |
Why?
|
| Inpatients | 2 | 2022 | 208 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 2223 | 0.290 |
Why?
|
| Receptors, Histamine H2 | 2 | 2017 | 4 | 0.290 |
Why?
|
| Phenylpropionates | 2 | 2018 | 2 | 0.290 |
Why?
|
| Tadalafil | 2 | 2018 | 4 | 0.290 |
Why?
|
| Myocardium | 6 | 2020 | 1204 | 0.290 |
Why?
|
| Tissue Donors | 4 | 2022 | 195 | 0.280 |
Why?
|
| Amyloid | 2 | 2017 | 39 | 0.280 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 121 | 0.270 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2019 | 185 | 0.270 |
Why?
|
| Time Factors | 13 | 2022 | 4655 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 365 | 0.270 |
Why?
|
| Acute Disease | 2 | 2019 | 658 | 0.260 |
Why?
|
| Nitroprusside | 2 | 2022 | 42 | 0.260 |
Why?
|
| Young Adult | 10 | 2022 | 5717 | 0.240 |
Why?
|
| Desmosomes | 2 | 2014 | 14 | 0.240 |
Why?
|
| Atrial Pressure | 2 | 2020 | 9 | 0.240 |
Why?
|
| Biomarkers | 5 | 2022 | 1593 | 0.230 |
Why?
|
| Proportional Hazards Models | 7 | 2022 | 792 | 0.220 |
Why?
|
| Survival Analysis | 3 | 2020 | 714 | 0.220 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2022 | 155 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2022 | 202 | 0.220 |
Why?
|
| Troponin I | 2 | 2016 | 34 | 0.210 |
Why?
|
| Models, Cardiovascular | 2 | 2020 | 133 | 0.210 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2022 | 47 | 0.200 |
Why?
|
| Puerperal Disorders | 1 | 2022 | 20 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 24 | 0.200 |
Why?
|
| Transplants | 1 | 2021 | 28 | 0.200 |
Why?
|
| Vena Cava, Superior | 1 | 2022 | 41 | 0.200 |
Why?
|
| Prosthesis Design | 3 | 2018 | 301 | 0.200 |
Why?
|
| Angiopoietin-2 | 1 | 2021 | 5 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2022 | 114 | 0.190 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2021 | 20 | 0.190 |
Why?
|
| Inhalation | 1 | 2020 | 11 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2021 | 622 | 0.190 |
Why?
|
| Propensity Score | 1 | 2021 | 117 | 0.180 |
Why?
|
| Early Diagnosis | 1 | 2021 | 122 | 0.180 |
Why?
|
| Hypertension | 2 | 2022 | 1535 | 0.180 |
Why?
|
| Milrinone | 1 | 2020 | 12 | 0.180 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 123 | 0.180 |
Why?
|
| Heart Rate Determination | 1 | 2019 | 1 | 0.180 |
Why?
|
| Thrombosis | 1 | 2021 | 218 | 0.180 |
Why?
|
| Resource Allocation | 1 | 2019 | 35 | 0.170 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1054 | 0.170 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2019 | 9 | 0.170 |
Why?
|
| Fontan Procedure | 1 | 2021 | 129 | 0.170 |
Why?
|
| Veterans | 2 | 2018 | 904 | 0.170 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 60 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2019 | 10 | 0.170 |
Why?
|
| Elasticity | 1 | 2019 | 103 | 0.170 |
Why?
|
| Morbidity | 1 | 2019 | 130 | 0.170 |
Why?
|
| Adipose Tissue | 1 | 2020 | 221 | 0.160 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 35 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2021 | 267 | 0.160 |
Why?
|
| Pulmonary Ventilation | 1 | 2018 | 28 | 0.160 |
Why?
|
| Mutation | 2 | 2014 | 1213 | 0.160 |
Why?
|
| ROC Curve | 2 | 2017 | 392 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 362 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 214 | 0.160 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 1851 | 0.160 |
Why?
|
| Length of Stay | 2 | 2022 | 780 | 0.160 |
Why?
|
| Scleroderma, Limited | 1 | 2018 | 5 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2020 | 193 | 0.150 |
Why?
|
| Myofibrils | 1 | 2018 | 35 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 189 | 0.150 |
Why?
|
| Eisenmenger Complex | 1 | 2017 | 4 | 0.150 |
Why?
|
| Vascular Capacitance | 1 | 2017 | 1 | 0.150 |
Why?
|
| Tennessee | 1 | 2017 | 11 | 0.150 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2017 | 21 | 0.150 |
Why?
|
| Intention | 1 | 2018 | 80 | 0.150 |
Why?
|
| Rest | 1 | 2017 | 78 | 0.150 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2017 | 10 | 0.150 |
Why?
|
| Sarcoidosis | 1 | 2018 | 77 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 514 | 0.150 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.150 |
Why?
|
| Prealbumin | 1 | 2017 | 25 | 0.140 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2017 | 21 | 0.140 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2016 | 5 | 0.140 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 9 | 0.140 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2017 | 99 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2018 | 141 | 0.140 |
Why?
|
| Disease Progression | 5 | 2019 | 1038 | 0.140 |
Why?
|
| Proteinuria | 1 | 2017 | 136 | 0.140 |
Why?
|
| Heart Function Tests | 1 | 2016 | 33 | 0.140 |
Why?
|
| False Negative Reactions | 1 | 2017 | 63 | 0.140 |
Why?
|
| Prevalence | 2 | 2020 | 1619 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2018 | 109 | 0.140 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 34 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2018 | 178 | 0.140 |
Why?
|
| Obesity | 2 | 2022 | 1076 | 0.140 |
Why?
|
| Chickens | 1 | 2017 | 232 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 596 | 0.140 |
Why?
|
| Endocardium | 1 | 2016 | 101 | 0.140 |
Why?
|
| Pulsatile Flow | 1 | 2016 | 20 | 0.140 |
Why?
|
| Amyloidosis | 1 | 2016 | 48 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2017 | 238 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 931 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 107 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.130 |
Why?
|
| Isosorbide Dinitrate | 1 | 2015 | 6 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2017 | 159 | 0.130 |
Why?
|
| Tricuspid Valve | 2 | 2016 | 42 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 164 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 35 | 0.130 |
Why?
|
| Biopsy | 4 | 2020 | 540 | 0.130 |
Why?
|
| Myocarditis | 1 | 2016 | 49 | 0.130 |
Why?
|
| Baltimore | 1 | 2015 | 34 | 0.130 |
Why?
|
| Age Factors | 3 | 2020 | 1864 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 12 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 18 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 148 | 0.130 |
Why?
|
| Collagen Type XVIII | 1 | 2015 | 2 | 0.130 |
Why?
|
| Glutamine | 1 | 2015 | 45 | 0.120 |
Why?
|
| Endostatins | 1 | 2015 | 11 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2017 | 344 | 0.120 |
Why?
|
| Glycolysis | 1 | 2015 | 79 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 31 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 232 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 207 | 0.120 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 98 | 0.120 |
Why?
|
| International Normalized Ratio | 1 | 2014 | 23 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 307 | 0.120 |
Why?
|
| Pericardium | 1 | 2014 | 97 | 0.120 |
Why?
|
| Defibrillators, Implantable | 3 | 2015 | 329 | 0.120 |
Why?
|
| Transplantation | 1 | 2013 | 23 | 0.110 |
Why?
|
| Penetrance | 1 | 2013 | 17 | 0.110 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 55 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2022 | 101 | 0.110 |
Why?
|
| Adaptation, Physiological | 3 | 2020 | 189 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2014 | 107 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1664 | 0.110 |
Why?
|
| Glucose | 1 | 2015 | 307 | 0.110 |
Why?
|
| Pharmacists | 1 | 2014 | 125 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 115 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2013 | 110 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2014 | 340 | 0.100 |
Why?
|
| Survivors | 1 | 2014 | 256 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 546 | 0.100 |
Why?
|
| Animals | 4 | 2017 | 20881 | 0.100 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2012 | 20 | 0.100 |
Why?
|
| Lung Compliance | 1 | 2011 | 10 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 448 | 0.100 |
Why?
|
| Coronary Occlusion | 1 | 2012 | 12 | 0.100 |
Why?
|
| Linear Models | 1 | 2013 | 521 | 0.100 |
Why?
|
| Stroke | 2 | 2022 | 2163 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 694 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 239 | 0.100 |
Why?
|
| Self Care | 1 | 2014 | 253 | 0.100 |
Why?
|
| Adolescent | 6 | 2022 | 8912 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2011 | 115 | 0.090 |
Why?
|
| Erythema | 1 | 2010 | 18 | 0.090 |
Why?
|
| Malnutrition | 1 | 2010 | 28 | 0.090 |
Why?
|
| Pulmonary Fibrosis | 1 | 2011 | 157 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2022 | 384 | 0.090 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2020 | 9 | 0.090 |
Why?
|
| Organ Size | 2 | 2020 | 242 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 86 | 0.080 |
Why?
|
| Echocardiography, Doppler | 2 | 2020 | 87 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2022 | 483 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 807 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1553 | 0.070 |
Why?
|
| Maryland | 2 | 2016 | 77 | 0.070 |
Why?
|
| Observer Variation | 2 | 2018 | 330 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 349 | 0.060 |
Why?
|
| Logistic Models | 2 | 2021 | 1420 | 0.060 |
Why?
|
| Ohio | 2 | 2015 | 64 | 0.060 |
Why?
|
| Fibrosis | 2 | 2017 | 371 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 649 | 0.060 |
Why?
|
| Ventricular Remodeling | 2 | 2017 | 318 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 627 | 0.060 |
Why?
|
| Coronary Angiography | 3 | 2017 | 866 | 0.050 |
Why?
|
| Hydrazones | 1 | 2023 | 11 | 0.050 |
Why?
|
| Diaphragm | 1 | 2022 | 22 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 786 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 90 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2022 | 15 | 0.050 |
Why?
|
| Heart Murmurs | 1 | 2021 | 6 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 79 | 0.050 |
Why?
|
| Dyspnea | 1 | 2022 | 87 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 186 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1753 | 0.050 |
Why?
|
| Aminobutyrates | 1 | 2022 | 94 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2015 | 453 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 12 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2022 | 184 | 0.050 |
Why?
|
| Angiopoietins | 1 | 2021 | 4 | 0.050 |
Why?
|
| Angiopoietin-1 | 1 | 2021 | 12 | 0.050 |
Why?
|
| Fluid Therapy | 1 | 2021 | 59 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 211 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 39 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 229 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2022 | 249 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2020 | 20 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 386 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 15 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 295 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 319 | 0.040 |
Why?
|
| Health Policy | 1 | 2021 | 221 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 652 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 169 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 867 | 0.040 |
Why?
|
| Colorado | 1 | 2018 | 26 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 507 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 500 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 15 | 0.040 |
Why?
|
| Netherlands | 1 | 2017 | 68 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2018 | 210 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 137 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 945 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2017 | 106 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.040 |
Why?
|
| Age Distribution | 1 | 2017 | 320 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1426 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 567 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2017 | 112 | 0.030 |
Why?
|
| Forecasting | 1 | 2017 | 277 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 219 | 0.030 |
Why?
|
| Giant Cells | 1 | 2016 | 14 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 112 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 208 | 0.030 |
Why?
|
| Accelerometry | 1 | 2015 | 61 | 0.030 |
Why?
|
| Desmocollins | 1 | 2015 | 6 | 0.030 |
Why?
|
| gamma Catenin | 1 | 2015 | 11 | 0.030 |
Why?
|
| Desmoglein 2 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Desmoplakins | 1 | 2015 | 14 | 0.030 |
Why?
|
| Plakophilins | 1 | 2015 | 19 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 260 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 880 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 368 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 770 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 163 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 159 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 506 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 188 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 233 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1330 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 216 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Calcium | 1 | 2018 | 929 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 141 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 301 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2014 | 392 | 0.030 |
Why?
|
| Warfarin | 1 | 2014 | 93 | 0.030 |
Why?
|
| Walking | 1 | 2015 | 241 | 0.030 |
Why?
|
| Motor Activity | 1 | 2015 | 621 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 281 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1738 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 947 | 0.020 |
Why?
|
| Drug-Eluting Stents | 1 | 2012 | 51 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2014 | 356 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2012 | 178 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2689 | 0.020 |
Why?
|
| Zinc | 1 | 2010 | 73 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 239 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1515 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2008 | 153 | 0.020 |
Why?
|
| Child | 1 | 2011 | 6405 | 0.010 |
Why?
|